July 2016

Amgen v. Apotex Decision

By: Sandra King  |   July 18, 2016

On July 5, 2016, the Federal Circuit issued its decision in Amgen v. Apotex affirming an order preliminarily enjoining Apotex from launching its version of Neulasta (pegfilgrastim)...Apotex contended that they were not required to provide post-licensure notice to Amgen and that such requirement may not be enforced by an injunction.

More Enhanced Damages on the Way?

By: Andreas Baltatzis & Emily A. Curtis  |   July 5, 2016

Following 2014 opinions changing the standards for attorneys’ fees in patent cases, the Supreme Court lowered the standard for awarding treble damages in patent infringement cases. See Halo Electronics, Inc. v. Pulse Electronics, Inc., Nos. 14-1513 and 14-1520 (S.Ct. June 13, 2016). This decision will affect more than the final award given in a suit.